SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech”, “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DSO), today announced that it has developed a novel tear samples and filed a provisional patent application for it with the United States Patent and Trademark Office.
Tear fluid analysis is a non-invasive method to obtain valuable information on the health status of various eye and systemic diseases, including dry eye, because tear fluid contains several molecular constituents that can be altered under different conditions. abnormal. However, obtaining adequate specimens for tear analysis requires an efficient collection method. Most tear sample collectors on the market use capillary designs that are intimidating to patients, difficult for untrained personnel to use, and expensive to manufacture.
AXIM’s new tear sample collection system provides a more comfortable experience for patients, has an indicator that appears on the strip when enough tear fluid has been absorbed, makes it easier for staff to use unformed and is extremely cost effective to mass produce scale. It’s especially important that it’s easy to mass-produce because of the growing prevalence of eye diseases, including dry eye, which affects about 6.8 percent of the US population.
AXIM plans to add this tear collection system to facilitate the advancement of its four point-of-care biomarker tests designed to expedite the diagnosis of dry eye disease. These tests include its recently announced Lacritin test, the MMP-9 test, and FDA 501(k) cleared tests for lactoferrin and IgE.
John Huemoeller, CEO of AXIM, said, “We believe this new system will play a vital role in advancing tear fluid collection technology and believe we will bring great value to patients and healthcare professionals. ocular. We are continually improving what we have acquired and what we have developed internally.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through testing for rapid diagnosis. The company has two of only five FDA-approved diagnostic tests for dye eye disease. For more information, please visit www.AXIMBiotech.com.
Statements made by Axim Biotechnologies Inc. in this press release may be “forward-looking” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform. Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to the lack of assurance that our diagnostic candidate will ever be approved for use by the US FDA or any equivalent foreign regulatory agency. In addition, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in sufficient quantities or that third parties with established ophthalmologists will enter into agreements or purchase from the Company, and even if The Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s reports and filings with the SEC, including our Annual Report on Form 10-K filed on April 15, 2022 and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc. undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unforeseen events, except as otherwise required by law. .
Kathryn Brown, Account Manager
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA